Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 protein + imiquimod
- Development stage
- Unknown
- Lead developer
- Ludwig Cancer Research
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Topical
01
Overview
NY-ESO-1 protein + imiquimod is an investigational cancer vaccine developed by the Ludwig Institute for Cancer Research for the treatment of malignant melanoma. The vaccine consists of a recombinant full-length NY-ESO-1 protein, a cancer-testis antigen expressed in approximately 20-30% of melanomas, administered in combination with imiquimod, a Toll-like receptor 7 (TLR7) agonist that serves as an adjuvant. The treatment regimen involves the topical application of imiquimod cream (Aldara) to precondition the skin, followed by the intradermal injection of the NY-ESO-1 protein. This combination is designed to elicit both humoral and cellular immune responses against NY-ESO-1-expressing tumor cells. It has been evaluated in Phase 1 clinical trials for patients with resected Stage IIB, IIC, and III malignant melanoma.
- Other names
- NY-ESO-1 protein vaccineNY-ESO1 protein vaccineNY-ESO 1 protein vaccineNY-ESO-1 protein with imiquimodNY-ESO1 protein with imiquimodNY-ESO 1 protein with imiquimod
02
Targets
TLR7 (Toll-like receptor 7)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 protein + imiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 protein + imiquimod.